Navigation Links
Calcium Channel Blocker Adalat GITS Offer Additional Benefits

ACTION-trial shows medical and economic advantages of nifedipine GITS therapy

LEVERKUSEN, Germany, March 28, 2007 – Two recently published articles in the Journal of Clinical Epidemiology provide further evidence that the use of the long-acting calcium channel blocker (CCB) nifedipine GITS (Adalat? GITS) has additional benefits beyond its blood pressure lowing effect. A first publication from Lubsen et al. (Journal of Clinical Epidemiology 2007; first published online) demonstrates that while the blood pressure lowering effect of nifedipine GITS did play a major role in the reduction of debilitating stroke and new overt heart failure, the anti-anginal and vascular protective effects of nifedipine GITS seem to be just as important in reducing cardiovascular events. A second publication by Poole-Wilson et al. (Journal of Clinical Epidemiology 2007; first published online) also demonstrates that a nifedipine GITS therapy in patients with stable angina can help contain healthcare expenses by reducing the need for additional medication and the use of expensive diagnostic and surgical procedures. Both these papers are based on analyses of the ACTION-database. ACTION (A Coronary Disease Trial Investigating Outcome with Nifedipine GITS) collected data from 7,665 patients with stable angina pectoris.

Lowering blood pressure helps reduce stroke and heart failure
The ACTION-trial showed that adding nifedipine GITS to a best practice angina pectoris therapy significantly reduced the incidence of any stroke or TIA (28%) and the development of new overt heart failure (29%). Using an innovative statistical approach, Lubsen et al. found that nifedipine GITS’ ability to lower systolic blood pressure was largely responsible for these impressive results. The reduction in the risks of coronary angiography and surgery, attributed to nifedipine GITS on the other hand, are likely to be d ue to an anti-anginal and a vascular protective effect.

Efficient utilization of resources
Using the ACTION data, Poole-Wilson et al. showed that adding nifedipine GITS to the best practice therapy reduced the need for additional medication and also the use of expensive diagnostic and surgical procedures together with their associated costs. Basis for the calculation of hospital expenses was a reference hospital in the Netherlands. The estimated cost of medication was also based on drug pricing in the Netherlands. In total the incremental cost of the nifedipine GITS therapy was just about € 69 per year, or about € 3,036 per year of event free survival.

Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG, Germany. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.

Bayer Schering Pharma
Bayer Schering Pharma AG, Germany, is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life.

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known an d unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


Related medicine technology :

1. Calcium Plaque Build-up in the Arteries Leads to Coronary Heart Disease in Multi-Ethnic Groups
2. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
3. Analyzers Offer Point-of-Care Lipid Panels
4. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
5. Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer
6. MUSC Research Offers Hope for Those Resistant to Depression Treatment
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
Post Your Comments:
(Date:10/13/2015)... YORK , Oct. 13, 2015 Pomerantz ... filed against Amicus Therapeutics, Inc. ("Amicus" or the "Company")(NASDAQ: ... filed in United States District Court, District of ... a class consisting of all persons or entities who ... 1, 2015 inclusive (the "Class Period"). This class action seeks ...
(Date:10/13/2015)... , Oct. 13, 2015  Vitamin Angels – ... and mothers in need of nutritional support - announced ... by the United Nations (UN). The UN,s newly established ... – are a recent follow up to the Millennium ... deadline for completion. The new 17 Global Goals intend ...
(Date:10/13/2015)... , Oct. 13, 2015   Generational Equity ... middle-market businesses, is pleased to announce the acquisition of ... in Largo, Florida , by Meridian ... on September 11, 2015. Florida ... --> Florida . To learn ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Hope; A Commitment to Cure last night at the Mandarin Oriental in New ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Vision Group ... Vision of San Diego, California. With brands including The LASIK Vision Institute and TLC ... making it the nationwide leader in laser vision correction. , Global Laser Vision will ...
(Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare Group , ... its partnership with WPC Healthcare , a provider of predictive analytics solutions ... data into an aggregated data repository necessary to perform reporting and analytics on ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
Breaking Medicine News(10 mins):